Compare ALEMBIC with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs VENUS REMEDIES - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC VENUS REMEDIES ALEMBIC/
VENUS REMEDIES
 
P/E (TTM) x 60.7 -9.7 - View Chart
P/BV x 5.2 0.6 810.3% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 ALEMBIC   VENUS REMEDIES
EQUITY SHARE DATA
    ALEMBIC
Mar-18
VENUS REMEDIES
Mar-18
ALEMBIC/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs72126 57.2%   
Low Rs3461 55.5%   
Sales per share (Unadj.) Rs4.7301.8 1.6%  
Earnings per share (Unadj.) Rs6.1-24.9 -24.5%  
Cash flow per share (Unadj.) Rs6.22.5 245.4%  
Dividends per share (Unadj.) Rs0.200-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs40.7293.3 13.9%  
Shares outstanding (eoy) m267.0312.34 2,163.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.30.3 3,635.9%   
Avg P/E ratio x8.7-3.8 -230.8%  
P/CF ratio (eoy) x8.536.7 23.1%  
Price / Book Value ratio x1.30.3 408.5%  
Dividend payout %3.30-   
Avg Mkt Cap Rs m14,1391,154 1,225.5%   
No. of employees `000NA0.9 0.0%   
Total wages/salary Rs m207393 52.8%   
Avg. sales/employee Rs ThNM4,026.1-  
Avg. wages/employee Rs ThNM425.0-  
Avg. net profit/employee Rs ThNM-331.8-  
INCOME DATA
Net Sales Rs m1,2553,724 33.7%  
Other income Rs m37023 1,645.3%   
Total revenues Rs m1,6253,747 43.4%   
Gross profit Rs m111395 28.1%  
Depreciation Rs m38338 11.2%   
Interest Rs m2354 0.5%   
Profit before tax Rs m442-275 -160.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2432 75.8%   
Profit after tax Rs m1,630-307 -531.1%  
Gross profit margin %8.910.6 83.5%  
Effective tax rate %5.4-11.5 -47.2%   
Net profit margin %129.8-8.2 -1,575.6%  
BALANCE SHEET DATA
Current assets Rs m1,8672,638 70.8%   
Current liabilities Rs m5912,305 25.7%   
Net working cap to sales %101.68.9 1,136.7%  
Current ratio x3.21.1 275.9%  
Inventory Days Days94135 69.6%  
Debtors Days Days7446 158.7%  
Net fixed assets Rs m1,7914,871 36.8%   
Share capital Rs m534123 432.8%   
"Free" reserves Rs m10,3243,496 295.3%   
Net worth Rs m10,8583,619 300.0%   
Long term debt Rs m411,374 3.0%   
Total assets Rs m11,5917,509 154.4%  
Interest coverage x260.90.2 117,000.8%   
Debt to equity ratio x00.4 1.0%  
Sales to assets ratio x0.10.5 21.8%   
Return on assets %14.10.6 2,229.8%  
Return on equity %15.0-8.5 -177.0%  
Return on capital %15.21.6 960.1%  
Exports to sales %1.50-   
Imports to sales %21.013.9 151.3%   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263517 51.0%   
Fx inflow Rs m190-   
Fx outflow Rs m264517 51.1%   
Net fx Rs m-244-517 47.3%   
CASH FLOW
From Operations Rs m236514 45.8%  
From Investments Rs m-224-123 182.0%  
From Financial Activity Rs m-27-387 6.9%  
Net Cashflow Rs m-154 -352.4%  

Share Holding

Indian Promoters % 64.0 32.9 194.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.2 111.1%  
FIIs % 9.7 0.6 1,672.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 66.4 39.3%  
Shareholders   54,701 20,121 271.9%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   ORCHID PHARMA  WYETH  ABBOTT INDIA  UNICHEM LAB  CIPLA  

Compare ALEMBIC With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Trades 279 Points Lower; Indicates Gap-Down Opening for Indian Stock Markets(SGX Nifty)

The SGX Nifty opened on a negative note today. At 8:10 am, it was trading down by 279 points, or 1.9% lower at 14,900 levels.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Feb 26, 2021 09:28 AM

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC - DISHMAN PHARMA COMPARISON

COMPARE ALEMBIC WITH

MARKET STATS